Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation.
The type 2 transmembrane serine protease matriptase is broadly expressed in human carcinomas and hematological cancers. The proteolytic activity of matriptase is a potential target of drugs and imaging probes. We assessed the fate of active matriptase following the induction of matriptase zymogen ac...
Main Authors: | Li-Ling Chu, Yuan Xu, Jie-Ru Yang, Yi-An Hu, Hsiang-Hua Chang, Hong-Yu Lai, Chun-Che Tseng, Hue-Yu Wang, Michael D Johnson, Jehng-Kang Wang, Chen-Yong Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3963879?pdf=render |
Similar Items
-
Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity.
by: Chun-Che Tseng, et al.
Published: (2017-01-01) -
Natural Endogenous Human Matriptase and Prostasin Undergo Zymogen Activation via Independent Mechanisms in an Uncoupled Manner.
by: Hui Chen Su, et al.
Published: (2016-01-01) -
Matriptase zymogen supports epithelial development, homeostasis and regeneration
by: Stine Friis, et al.
Published: (2017-06-01) -
ErbB-2 Signaling Is Involved in Matriptase Zymogen Activation in Human Prostate Cancer Cells
by: Shang-Ru Wu, et al.
Published: (2008) -
The mechanism of matriptase activation
by: Cheng-Li Huang, et al.
Published: (2008)